Short answer
Coherus Oncology, Inc. (CHRS) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Board-declared special dividend of contingent value rights to shareholders.
Coherus Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Board-declared special dividend of contingent value rights to shareholders
- FAQ addressing the CVR dividend available through Coherus’s investor-relations website
- Press release and FAQ exhibits provide the operative terms and shareholder guidance for the distribution
Item 8.01 · Other Events
- One CVR per common share held at 5:00 p.m. ET on September 30, 2026
- Payments depend on net cash proceeds from Legacy BioSim Asset monetization during October 7, 2026–October 7, 2028
- Investment bank retained to support sale of patents, royalties, cell lines, and related materials
- Loan Agreement restricts Legacy BioSim Asset dispositions and CVR payments, potentially limiting timing or proceeds
- CVRs are non-transferable, unlisted, non-interest-bearing contractual rights without voting, dividend, or ownership rights
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Coherus Oncology, Inc. 8-K filings
Get the next CHRS 8-K as it lands
Follow CHRS for push alerts, or ask the research agent what this filing means.